Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Down 70.4% in June

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 20,390 shares, a drop of 70.4% from the May 31st total of 68,896 shares. Based on an average daily volume of 76,356 shares, the short-interest ratio is presently 0.3 days. Currently, 0.3% of the shares of the company are sold short.

Matinas Biopharma Stock Performance

NYSEAMERICAN:MTNB opened at $0.66 on Tuesday. The firm’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.64. The firm has a market cap of $4.26 million, a price-to-earnings ratio of -0.33 and a beta of 1.67. Matinas Biopharma has a one year low of $0.48 and a one year high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.